IP Library Granted Patent US 10,822,623
Granted Patent B2
US 10,822,623 · App. 16/243,332 · Granted Nov 3, 2020

Synthetic biochemistry molecular purge valve module that maintain co-factor balance

Inventors: James U. Bowie (Culver City, CA); Paul H. Opgenorth (Los Angeles, CA); Tyler P. Korman (Sierra Madre, CA)
Assignee: The Regents of the University of California
C12P5/007C12N9/0008C12N9/1029C12P7/625C12Y102/01051C12Y106/99001C12Y108/01004C12Y203/01012
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,822,623
App. No.
16/243,332
Granted
Nov 3, 2020
Kind
B2
Abstract

The disclosure provides a metabolic pathway for producing a metabolite, the metabolic pathway having a co-factor purge valve system for recycling a cofactor used in the metabolic pathway.

Claims (22)

1. A recombinant, artificial or engineered metabolic pathway comprising a plurality of enzymatic steps that converts a substrate to a product, wherein the pathway produces an unbalanced production of a cofactor, said pathway comprising:

a first cofactor-dependent enzyme that is capable of converting a first substrate to a second substrate, said enzyme producing the unbalanced production of a cofactor; and

a second cofactor-dependent enzyme comprising an NADH or an NADPH oxidase that recycles the cofactor.

2. The recombinant, artificial or engineered pathway of claim 1 , wherein the co-factor is an oxidizing/reducing co-factor.

3. The recombinant, artificial or engineered pathway of claim 2 , wherein the oxidizing/reducing co-factor is selected from the group consisting of NAD + /NADH, NADP + /NADPH and FAD + /FADH.

4. The recombinant, artificial or engineered pathway of claim 1 , wherein the cofactor comprises NAD + /NADH or NADP + /NADPH.

5. The recombinant, artificial or engineered pathway of claim 1 , wherein the first cofactor-dependent enzyme comprises an NADH or an NADPH dehydrogenase.

6. The recombinant, artificial or engineered pathway of claim 5 , wherein the NADH dehydrogenase is a NADH pyruvate dehydrogenase complex.

7. The recombinant, artificial or engineered pathway of claim 6 , wherein the NADH pyruvate dehydrogenase complex comprises a pyruvate dehydrogenase subunit a, a pyruvate dehydrogenase subunit b, a dihydrolipoamide acetyltransferase, and a dihydrolipoamide dehydrogenase.

8. The recombinant, artificial or engineered pathway of claim 7 , wherein the pyruvate dehydrogenase subunit a comprises a sequence that has at least 90% sequence identity to SEQ ID NO: 1, wherein the pyruvate dehydrogenase subunit b comprises a sequence that has at least 90% sequence identity to SEQ ID NO: 2, wherein the dihydrolipoamide acetyltransferase has at least 90% sequence identity to SEQ ID NO: 3, and wherein the dihydrolipoamide dehydrogenase has at least 90% sequence identity to SEQ ID NO: 5, wherein the complex converts pyruvate to acetyl-CoA.

9. The recombinant, artificial or engineered pathway of claim 7 , wherein the pyruvate dehydrogenase subunit a comprises a sequence that has at least 90% sequence identity to SEQ ID NO: 1, wherein the pyruvate dehydrogenase subunit b comprises a sequence that has at least 90% sequence identity to SEQ ID NO: 2, wherein the dihydrolipoamide acetyltransferase has at least 90% sequence identity to SEQ ID NO: 3, and wherein the dihydrolipoamide dehydrogenase has at least 90% sequence identity to SEQ ID NO: 7 and preferentially uses NADP + , wherein the complex converts pyruvate to acetyl-CoA.

10. The recombinant, artificial or engineered pathway of claim 5 , wherein the NADPH dehydrogenase is a member of a NADPH pyruvate dehydrogenase complex.

11. The recombinant, artificial or engineered pathway of claim 10 , wherein the NADPH pyruvate dehydrogenase complex comprises a pyruvate dehydrogenase subunit a, a pyruvate dehydrogenase subunit b, a dihydrolipoamide acetyltransferase, and a mutant dihydrolipoamide dehydrogenase the preferentially uses NADP + .

12. The recombinant, artificial or engineered pathway of claim 1 , wherein the NADH or the NADPH oxidase is a NoxE or homolog thereof.

13. The recombinant, artificial or engineered pathway of claim 12 , wherein the NADH or the NADPH oxidase comprises a sequence that has at least 50% sequence identity to SEQ ID NO: 10.

14. The recombinant, artificial or engineered pathway of claim 1 , wherein the pathway is in a cell-free system.

15. The recombinant, artificial or engineered pathway of claim 1 , wherein the pathway is in a living cell.

16. The recombinant, artificial or engineered pathway of claim 1 , wherein the recombinant, artificial or engineered pathway produces PHB.

17. The recombinant, artificial or engineered pathway of claim 1 , wherein the recombinant, artificial or engineered pathway produces ethanol.

18. The recombinant, artificial or engineered pathway of claim 1 , wherein the recombinant, artificial or engineered pathway produces lactate.

19. An enzymatic system comprising a metabolic pathway including a plurality of enzymes for converting a substrate to a product, the metabolic pathway having an unbalanced utilization of reducing/oxidizing cofactors, wherein the enzymatic system comprises a metabolic purge valve comprising an NADH pyruvate dehydrogenase and a NADH/NADPH oxidase.

20. A recombinant polypeptide comprising a sequence that has at least 99% sequence identity to SEQ ID NO: 5 and comprising the mutations E206V, G207R, A208K, and S213R, wherein the polypeptide has dihydrolipoamide dehydrogenase activity.

Assignments (2)
CONFIRMATORY LICENSE Recorded Apr 13, 2020
From: UNIVERSITY OF CALIFORNIA LOS ANGELES
To: UNITED STATES DEPARTMENT OF ENERGY
Reel/Frame 052383/0901 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2019
From: BOWIE, JAMES U.; OPGENORTH, PAUL H.; KORMAN, TYLER P.
To: REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 048084/0671 →
Continuity (3)
Continuation 15127351
Provisional Application 61974311 · Apr 2, 2014
Related Publication 20190271010A1 · Sep 5, 2019